The Centers for Medicare & Medicaid Services (CMS), linked to the United States Department of Health and Human Services (HHS), will issue an official notice with the proposal to authorize CBD coverage by Medicare. The measure, set to take effect in 2027, signals a review of current policies. The goal is to facilitate access to cannabis-derived products in American federal health plans.

Medicare is the US federal health insurance program for individuals aged 65 and older, as well as citizens with certain disabilities and end-stage renal diseases. The system is divided into different parts (A, B, C, and D), covering specific services. The new directive proposes to change the existing rules, which currently prohibit reimbursement for any "cannabis products."

Under the new text, the restriction would only apply to items illegal under state or federal laws, including the Federal Food, Drug, and Cosmetic Act (FFDCA). In practice, patients in states where the substance is legalized could benefit from CBD coverage by Medicare. For this, the product must comply with federal legislation.

Political Context of CBD Coverage by Medicare

The change comes about a month after meetings between the Secretary of Health and Human Services, Robert F. Kennedy Jr., and sector representatives. Kennedy Jr. met with Howard Kessler, CEO of the Commonwealth Project, an organization advocating for the therapeutic use of the substance.

The political movement surrounding CBD coverage by Medicare gained momentum in late September. At that time, President Donald Trump promoted a video from the Commonwealth Project on the social network Truth Social. The content described the initiative as crucial for public health.

"It's time to educate doctors about the endocannabinoid system, provide Medicare coverage for CBD, and give millions of seniors the support they deserve," the video text read.

Market and Economic Impact

The disclosure of the potential regulatory change immediately impacted the financial market, as reported by Investing.com. Cannabis sector company stocks rose on Wednesday following preliminary information released by Bloomberg. Tilray Inc rose by 3.7%, leading the gains, followed by increases in Curaleaf Holdings Inc and Innovative Industrial Properties Inc.

In addition to the stock appreciation, the material released cited Fox News data projecting an annual $64 billion economy. This cost reduction would occur if cannabis were fully integrated into the healthcare system. Documents suggest that the initial version of CBD coverage by Medicare may focus on seniors undergoing oncological treatment and palliative care.

Regulatory Aspects of CBD Coverage by Medicare

The CMS highlighted in a document that hemp-derived products meeting legal definitions are not controlled substances. The agency noted that the rule would allow the offering of items such as shelled hemp seeds, protein powder, and seed oil. These materials are already recognized as Generally Recognized as Safe (GRAS) by the Food and Drug Administration (FDA).

“If such products comply with all other applicable federal laws, including any future changes in the definition of hemp and provisions of the FFDCA, then they are not illegal under federal law,” the CMS stated regarding CBD coverage by Medicare.

Despite the openness, the sector faces legislative challenges. Changes in federal hemp legislation, expected for next year, along with pressure from various states, may limit the scope of products. The current wording of laws may impose strict THC concentration limits, significantly raising extraction costs to ensure legal compliance.

With information from Marijuana Moment